quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 8, 2025

Is L3Harris the Best Defense Play Amid Increased Military Spending?

View original at finance.yahoo.com
Is L3Harris the Best Defense Play Amid Increased Military Spending? This article first appeared on GuruFocus. L3Harris Technologies (NYSE: LHX) may not carry the household name status of defence giants Lockheed or Raytheon, but I wouldn't mistake that for irrelevance…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • L3Harris is initiating a Buy rating

    80% confidence

  • Wall Street has Strong Buy rating overall on L3Harris

    80% confidence

  • Forward EPS guidance appears conservative given strong order momentum and robust defense budget

    80% confidence

  • L3Harris guidance represents about 7% growth in EPS

    80% confidence

  • Several analysts see upside to $280 range with some looking down to $212

    80% confidence

  • Recent analyst downward revisions tied to accounting adjustments, not underlying demand issues

    80% confidence

  • The Aerojet acquisition de-risks L3Harris business by adding long-cycle, platform-agnostic revenue stream

    80% confidence

  • L3Harris may be underestimated by the market despite being well-positioned strategically

    80% confidence

  • L3Harris offers compelling mix of quality and growth, recommendation is Buy

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Is L3Harris the Best Defense Play Amid Increased Military Spending? — Source | Via News | pt.VIA.NEWS